Figure 1From: Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance statusSurvival Function. The median overall survival (MS) was 10.1 months (95% CI 3.4–16.8 months), and 1-year survival rate 45% for advanced NSCLC patients with PS 3/4 received gefitinib treatment.Back to article page